IL5 and colitis: In response to IL-2/JES6-1 immunocomplex administration and increased levels of IL-5, the augmented number and activation status of eosinophils may tip the balance in the pro-inflammatory direction, which may explain our observed beneficial effect of combined IL-2/JES6-1 immunocomplex and IL-5 blockade in the DSS model of colitis.